PL2313087T3 - Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonu - Google Patents
Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonuInfo
- Publication number
- PL2313087T3 PL2313087T3 PL09757601T PL09757601T PL2313087T3 PL 2313087 T3 PL2313087 T3 PL 2313087T3 PL 09757601 T PL09757601 T PL 09757601T PL 09757601 T PL09757601 T PL 09757601T PL 2313087 T3 PL2313087 T3 PL 2313087T3
- Authority
- PL
- Poland
- Prior art keywords
- dosage form
- pharmaceutical dosage
- immediate release
- indolinone derivative
- indolinone
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Business, Economics & Management (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Entrepreneurship & Innovation (AREA)
- Surgery (AREA)
- Educational Administration (AREA)
- Educational Technology (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157750 | 2008-06-06 | ||
| PCT/EP2009/056895 WO2009147220A1 (en) | 2008-06-06 | 2009-06-04 | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| EP09757601.1A EP2313087B2 (en) | 2008-06-06 | 2009-06-04 | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL2313087T3 true PL2313087T3 (pl) | 2019-05-31 |
| PL2313087T5 PL2313087T5 (pl) | 2024-03-04 |
Family
ID=41017080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09757601.1T PL2313087T5 (pl) | 2008-06-06 | 2009-06-04 | Farmaceutyczna postać dawkowania do natychmiastowego uwalniania pochodnej indolinonu |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20110190318A1 (pl) |
| EP (1) | EP2313087B2 (pl) |
| JP (2) | JP5583119B2 (pl) |
| KR (1) | KR20110022586A (pl) |
| CN (1) | CN102056599A (pl) |
| AR (1) | AR072060A1 (pl) |
| AU (1) | AU2009254556B2 (pl) |
| BR (1) | BRPI0913235A2 (pl) |
| CA (1) | CA2726648A1 (pl) |
| CL (1) | CL2010001362A1 (pl) |
| CO (1) | CO6280468A2 (pl) |
| CY (1) | CY1121272T1 (pl) |
| DK (1) | DK2313087T4 (pl) |
| EA (1) | EA201001857A1 (pl) |
| EC (1) | ECSP10010717A (pl) |
| ES (1) | ES2711913T5 (pl) |
| FI (1) | FI2313087T4 (pl) |
| HR (1) | HRP20190181T4 (pl) |
| HU (1) | HUE042524T2 (pl) |
| IL (1) | IL209055A0 (pl) |
| LT (1) | LT2313087T (pl) |
| MA (1) | MA32386B1 (pl) |
| MX (1) | MX338001B (pl) |
| PE (1) | PE20100050A1 (pl) |
| PL (1) | PL2313087T5 (pl) |
| PT (1) | PT2313087T (pl) |
| RS (1) | RS58280B2 (pl) |
| SG (1) | SG191607A1 (pl) |
| SI (1) | SI2313087T2 (pl) |
| TR (1) | TR201901579T4 (pl) |
| TW (1) | TW201002692A (pl) |
| UA (1) | UA107560C2 (pl) |
| UY (1) | UY31876A (pl) |
| WO (1) | WO2009147220A1 (pl) |
| ZA (1) | ZA201007972B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| HRP20180709T1 (hr) * | 2008-06-06 | 2018-06-15 | Boehringer Ingelheim International Gmbh | Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona |
| JP2015532272A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| JP6453319B2 (ja) | 2013-06-04 | 2019-01-16 | モノソル リミテッド ライアビリティ カンパニー | 水溶性フィルムシール溶液、関連する方法、および関連する物品 |
| CA2919498C (en) | 2013-07-31 | 2023-07-25 | Windward Pharma, Inc. | Aerosol nintedanib compounds and uses thereof |
| MX393691B (es) | 2015-06-06 | 2025-03-24 | Cloudbreak Therapeutics Llc | Composiciones y metodos para tratar pterigion. |
| AU2017274195B2 (en) | 2016-06-02 | 2022-04-07 | Ads Therapeutics Llc | Compositions and methods of using nintedanib for improving glaucoma surgery success |
| JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
| JP2020512364A (ja) * | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 筋ジストロフィーの処置方法において使用するためのニンテダニブ |
| BR112020003973A2 (pt) | 2017-10-23 | 2020-09-01 | Boehringer Ingelheim International Gmbh | combinação de agentes ativos para o tratamento de doenças pulmonares intersticiais fibrosantes progressivas (pf-ild) |
| DK3761980T3 (da) | 2018-03-07 | 2024-01-29 | Pliant Therapeutics Inc | Aminosyreforbindelser og fremgangsmåder til anvendelse |
| EP4125890A1 (en) | 2020-04-01 | 2023-02-08 | Boehringer Ingelheim International GmbH | Use of biomarkers in the treatment of fibrotic conditions |
| EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
| JP2025525881A (ja) | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3579384D1 (de) | 1984-07-24 | 1990-10-04 | Scherer Gmbh R P | Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung. |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SI1948180T1 (sl) | 2005-11-11 | 2013-06-28 | Boehringer Ingelheim International Gmbh | Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje |
| SI2985025T1 (en) * | 2008-06-06 | 2018-04-30 | Boehringer Ingelheim International Gmbh | A pharmaceutical combination |
| HRP20180709T1 (hr) * | 2008-06-06 | 2018-06-15 | Boehringer Ingelheim International Gmbh | Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona |
| EP2387401A1 (en) * | 2009-01-14 | 2011-11-23 | Boehringer Ingelheim International GmbH | Method for treating colorectal cancer |
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| EP2429520A1 (en) * | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
-
2009
- 2009-04-06 UA UAA201100096A patent/UA107560C2/ru unknown
- 2009-06-04 DK DK09757601.1T patent/DK2313087T4/da active
- 2009-06-04 MX MX2010013092A patent/MX338001B/es active IP Right Grant
- 2009-06-04 EA EA201001857A patent/EA201001857A1/ru unknown
- 2009-06-04 TR TR2019/01579T patent/TR201901579T4/tr unknown
- 2009-06-04 SI SI200931930T patent/SI2313087T2/sl unknown
- 2009-06-04 JP JP2011512134A patent/JP5583119B2/ja active Active
- 2009-06-04 BR BRPI0913235A patent/BRPI0913235A2/pt not_active IP Right Cessation
- 2009-06-04 EP EP09757601.1A patent/EP2313087B2/en active Active
- 2009-06-04 HU HUE09757601A patent/HUE042524T2/hu unknown
- 2009-06-04 LT LTEP09757601.1T patent/LT2313087T/lt unknown
- 2009-06-04 ES ES09757601T patent/ES2711913T5/es active Active
- 2009-06-04 PE PE2009000780A patent/PE20100050A1/es not_active Application Discontinuation
- 2009-06-04 HR HRP20190181TT patent/HRP20190181T4/hr unknown
- 2009-06-04 PT PT09757601T patent/PT2313087T/pt unknown
- 2009-06-04 CA CA2726648A patent/CA2726648A1/en not_active Abandoned
- 2009-06-04 WO PCT/EP2009/056895 patent/WO2009147220A1/en not_active Ceased
- 2009-06-04 FI FIEP09757601.1T patent/FI2313087T4/fi active
- 2009-06-04 US US12/995,893 patent/US20110190318A1/en not_active Abandoned
- 2009-06-04 PL PL09757601.1T patent/PL2313087T5/pl unknown
- 2009-06-04 KR KR1020107027313A patent/KR20110022586A/ko not_active Ceased
- 2009-06-04 SG SG2013040332A patent/SG191607A1/en unknown
- 2009-06-04 RS RS20190128A patent/RS58280B2/sr unknown
- 2009-06-04 CN CN200980121070XA patent/CN102056599A/zh active Pending
- 2009-06-04 AU AU2009254556A patent/AU2009254556B2/en active Active
- 2009-06-05 TW TW098118827A patent/TW201002692A/zh unknown
- 2009-06-05 AR ARP090102040A patent/AR072060A1/es unknown
- 2009-06-08 UY UY0001031876A patent/UY31876A/es not_active Application Discontinuation
-
2010
- 2010-11-01 IL IL209055A patent/IL209055A0/en unknown
- 2010-11-08 ZA ZA2010/07972A patent/ZA201007972B/en unknown
- 2010-12-03 CO CO10152530A patent/CO6280468A2/es not_active Application Discontinuation
- 2010-12-06 CL CL2010001362A patent/CL2010001362A1/es unknown
- 2010-12-06 MA MA33403A patent/MA32386B1/fr unknown
- 2010-12-23 EC EC2010010717A patent/ECSP10010717A/es unknown
-
2013
- 2013-03-08 US US13/790,334 patent/US20130203773A1/en not_active Abandoned
-
2014
- 2014-02-10 US US14/176,478 patent/US20140163040A1/en not_active Abandoned
- 2014-02-28 JP JP2014039871A patent/JP5992937B2/ja active Active
-
2019
- 2019-02-19 CY CY20191100212T patent/CY1121272T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201007972B (en) | Pharmaceutical dosage form for immediate release of an indolinone derivative | |
| ZA201007636B (en) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | |
| ZA201102406B (en) | Pharmaceutical composition for modified release | |
| IL207512A0 (en) | Pharmaceutical composition for poorly soluble drugs | |
| IL214628A0 (en) | Sustained release oral dosage forms of an r- baclofen prodrug | |
| IL213545A0 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| IL213546A0 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| ZA201105572B (en) | Pharmaceutical composition for oral administration | |
| ZA200810178B (en) | Pharmaceutical compositions for sustained release of phenyephrine | |
| ZA201101053B (en) | Pharmaceutical compositions of samatotrophic hormones | |
| HUE037915T2 (hu) | Gyógyszerészeti készítmények aktív vegyületek felszabadítására | |
| EP2343076A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| GB0802873D0 (en) | Pharmaceutical dosage forms for delayed and extended release | |
| SMT202100059T1 (it) | Composizione farmaceutica per il rilascio modificato | |
| HK1164734A (en) | Sustained release oral dosage forms of an r-baclofen prodrug | |
| ZA201001127B (en) | Pharmaceutical formulation for extended release |